E Fund Management Co. Ltd. Purchases 2,151 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

E Fund Management Co. Ltd. grew its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 13.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,785 shares of the company’s stock after acquiring an additional 2,151 shares during the quarter. E Fund Management Co. Ltd.’s holdings in BridgeBio Pharma were worth $488,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of BBIO. Steward Partners Investment Advisory LLC lifted its position in shares of BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after buying an additional 472 shares during the period. Advisors Asset Management Inc. lifted its position in shares of BridgeBio Pharma by 56.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock worth $117,000 after buying an additional 1,645 shares during the period. Swiss National Bank lifted its position in shares of BridgeBio Pharma by 1.1% during the 3rd quarter. Swiss National Bank now owns 219,300 shares of the company’s stock worth $5,583,000 after buying an additional 2,400 shares during the period. Quarry LP lifted its position in shares of BridgeBio Pharma by 33.3% during the 3rd quarter. Quarry LP now owns 10,000 shares of the company’s stock worth $255,000 after buying an additional 2,500 shares during the period. Finally, Arizona State Retirement System lifted its position in shares of BridgeBio Pharma by 9.7% during the 4th quarter. Arizona State Retirement System now owns 35,470 shares of the company’s stock worth $973,000 after buying an additional 3,141 shares during the period. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Stock Performance

NASDAQ BBIO opened at $31.57 on Friday. The stock has a fifty day moving average of $33.16 and a 200-day moving average of $28.58. The stock has a market capitalization of $6.00 billion, a P/E ratio of -11.08 and a beta of 1.07. BridgeBio Pharma, Inc. has a 52 week low of $21.62 and a 52 week high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The company had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million. Equities research analysts forecast that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BBIO shares. Bank of America raised their target price on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Citigroup lifted their price objective on BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Evercore ISI lifted their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research report on Monday, December 23rd. Scotiabank lifted their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Friday, February 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $49.00 price objective on shares of BridgeBio Pharma in a research report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $51.55.

Insider Buying and Selling

In related news, CFO Brian C. Stephenson sold 4,148 shares of BridgeBio Pharma stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total transaction of $149,991.68. Following the completion of the sale, the chief financial officer now directly owns 102,464 shares of the company’s stock, valued at $3,705,098.24. The trade was a 3.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of BridgeBio Pharma stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $32.96, for a total value of $197,760,000.00. Following the sale, the insider now directly owns 19,260,971 shares of the company’s stock, valued at approximately $634,841,604.16. This trade represents a 23.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 9,579,739 shares of company stock valued at $323,171,901 over the last three months. Company insiders own 24.66% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.